com_NN Emoluments_NNS of_IN Directors_NNS The_DT aggregate_JJ remuneration_NN ,_, excluding_VBG pension_NN contributions_NNS ,_, paid_VBN to_TO or_CC accrued_VBN for_IN all_DT Directors_NNS and_CC officers_NNS of_IN the_DT Company_NN for_IN services_NNS in_IN all_DT capacities_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD was_VBD 10_CD million_CD $_$ 17_CD million_CD ._.
Remuneration_NNP of_IN individual_JJ Directors_NNS is_VBZ set_VBN out_RP below_IN in_IN sterling_NN and_CC US_NNP dollars_NNS ._.
All_DT salaries_NNS ,_, fees_NNS and_CC bonuses_NNS for_IN Directors_NNS are_VBP established_VBN in_IN sterling_NN ._.
As_IN described_VBN fully_RB in_IN the_DT AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ Information_NN 2003_CD and_CC noted_VBD on_IN page_NN 24_CD of_IN the_DT Annual_JJ Review_NNP 2004_CD ,_, compensation_NN payments_NNS to_TO Hkan_NNP Mogren_NNP and_CC ke_NNP Stavling_NNP were_VBD 450,000_CD $_$ 818,000_CD and_CC 435,000_CD $_$ 791,000_CD ,_, respectively_RB and_CC are_VBP included_VBN within_IN Other_JJ in_IN the_DT above_JJ tables_NNS ._.
